By Anna Rose Welch, editor, Biosimilar Development
I reached out to Dr. Jeffrey Patton, the CEO of Tennessee Oncology and president of physician services and board member at OneOncology, to better understand the overall decision to implement Amgen's Kanjinti and Mvasi biosimilars, as well as which mechanisms he believes will help improve biosimilar usage in oncology in the months and years ahead.
By Vicky Xia and Leo Cai Yang, BioPlan Associates, Inc.
Fueled by the country’s large population and rapid urbanization, China’s biopharma segment has experienced double-digit growth for the past decade, and the landscape is poised for robust growth for the near future.
Biologics are the next great step for the pharmaceutical industries. The double-edged sword is that, as the molecules become more and more complex, our need for control and understanding becomes greater.
The transfer of a monoclonal antibody (mAb) production process between scales, often referred to as scale-up or scale-down, is a difficult task. This study reviews moving a monoclonal antibody production process from a microscale bioreactor to the Xcellerex XDR single-use platform.
C5 presents its Global Legal and Regulatory Summit on Biosimilars, where the latest legal and regulatory ramifications for biosimilar stakeholders will be tracked. Be part of interactive discussions that will enable you to develop a holistic strategy for maximizing commercial results for your biosimilar products. Gain insights from key global industry stakeholders including Amgen, Formycon AG, and Glenmark Pharmaceuticals. 10% Off with Code: D10-510-510BX01